Ignite Creation Date:
2024-05-05 @ 11:33 PM
Last Modification Date:
2024-10-26 @ 10:35 AM
Study NCT ID:
NCT01358123
Status:
UNKNOWN
Last Update Posted:
2015-09-25
First Post:
2011-05-18
Brief Title:
Value of Von Willebrand Factor in Portal Hypertension
Sponsor:
Medical University of Vienna
Organization:
Medical University of Vienna
Study Overview
Official Title:
Von Willebrand Factor As Non-Invasive Predictor Of Clinically Significant Portal Hypertension And Mortality In Patients With Liver Cirrhosis
Status:
UNKNOWN
Status Verified Date:
2015-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In patients with liver cirrhosis elevated levels of von Willebrand factor antigen vWF-Ag are found frequently but the clinical significance is unclear vWF-Ag plays an important role in primary haemostasis and development of thrombotic vascular obliteration is discussed as a possible mechanism leading to portal hypertension Invasive measurement of hepatic venous pressure gradient HVPG is the current gold standard for the diagnosis of portal hypertension The investigators hypothesize that vWF-Ag levels in plasma may correlate with portal pressure and predict clinically significant portal hypertension CSPH HVPG 10mmHg and its complications
Detailed Description:
Patients with alcoholic viral chronic hepatitis C and cryptogenic liver cirrhosis are included Portal hemodynamics are assessed by HVPG measurement vWF-Ag levels were measured by ELISA Results will be compared 3 and 6 months mortality will be recorded
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None